Emerging retatrutide, a twin -action medication targeting equally GLP-1 and GIP receptors, is generating considerable excitement within the healthcare community. Early clinical trials have shown impressive reductions in overall size and improvements in metabolic markers for patients with obesity . Researchers believe this unique approach could repr